Authors
Latest:
Financial toxicity is a growing concern in urologic oncology"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.
Latest:
Management of BCG-unresponsive NMIBC"An alternative off-label option for patients with BCG-unresponsive NMIBC is sequential intravesical gemcitabine and docetaxel (Gem/Doce)," write Rachel Passarelli, MD, and Vignesh T. Packiam, MD.
Latest:
Upper tract urothelial carcinoma: An in-depth review for urologists"On-going innovation will continue to drive UTUC management forward, and with it will come on-going challenges of how to best study a relatively rare disease," write the authors.
Latest:
Study shows HIFU noninferior to prostatectomy for localized prostate cancerTreating patients with localized prostate cancer with high-intensity focused ultrasound led to noninferior salvage treatment-free survival vs radical prostatectomy.
Latest:
Biomarker may predict MIBC status following neoadjuvant chemo"The biomarker is better at predicting presence of disease than absence, and the reason that that's important is that's how we can think about the biomarker aiding in careful clinical assessment of patients," says Elizabeth R. Plimack, MD, MS, FASCO.
Latest:
Conference Convenes Experts in the Field of Nuclear Medicine to Advance Prostate Cancer CareThe conference explored the current and future use of PSMA-PET imaging and PSMA radioligand therapy to improve the clinical care of patients with prostate cancer.
Latest:
How to perform office-based blue light cystoscopyBLC with hexaminolevulinate can be an easily replicable procedure in patients with non–muscle-invasive bladder cancer.
Latest:
Trends in coding audits and what physicians can expectRecent trends in medical audits and what physicians can expect with the CMS changes in 2021 to the documentation of E/M codes.
Latest:
Transurethral resection of the bladder tumor: Standard technique and new advancementsImprovement in imaging modalities may help in performance of transurethral resection of the bladder tumor.
Latest:
Smaller medical practices increasingly targeted for cyber attacksPatient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.
Latest:
Expert shares key cybersecurity fundamentals and best practicesCybersecurity training is vital because it is mandated by HIPAA.
Latest:
Future Directions for the Management of Advanced Prostate CancerBobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.
Latest:
Unmet Needs and Treatment Gaps in Prostate CancerThe panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods.
Latest:
Phase 3 CELLEBRATE trial testing regenerative stem cell-based therapy to improve urinary control for womenThe therapy, known as Autologous Muscle Derived Cells for Urinary Sphincter Repair (iltamiocel), involves a medical procedure in which a participant’s own muscle cells are collected, processed, and then injected into the tissues of the urinary passage.
Latest:
Future Research and Development of Abiraterone Combination TherapiesIn this video, experts share their opinion on the potential for novel combination therapies involving micronized abiraterone, particularly in conjunction with PARP inhibitors like olaparib or niraparib, as evidenced in clinical trials such as PROpel and MAGNITUDE. Additionally, they highlight other potential novel combinations like abiraterone with prednisolone and enzalutamide (STAMPEDE trial), and the integration of abiraterone in treatments involving radiation and androgen deprivation therapy (ADT).
Latest:
Future Directions in PSMA-PET ImagingLooking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
Latest:
Expert urges widespread adoption of next-generation sequencing among physiciansNGS empowers clinicians to take proactive measures to prevent disease, enables more precise diagnosis, and provides better insight on the best treatment option.
Latest:
UT Money Matters: Roth IRA conversionsExpert insight on pros, cons and optimal strategies when considering converting a traditional IRA to a Roth IRA.
Latest:
How to implement an ERAS pathway in your urology practiceProgram encompasses patient counseling, anesthetic planning, and early mobilization.
Latest:
Urologist discusses Women’s Urologic Health Alliance, parental leave"[A parental leave policy] is something that this generation, both men and women, not only are going to be happy to see, they're going to expect it," says Kari Bailey, MD.
Latest:
How to approach immune checkpoint inhibitor therapy in prostate cancerNext-generation sequencing identifies subtypes that may benefit from immune checkpoint inhibitors.
Latest:
Advanced bladder cancer patients could keep their bladder under new treatment regime, clinical trial showsAn approach combining chemotherapy and immunotherapy could help preserve quality of life.
Latest:
Enrollment goal met in phase 3 SOLAR-RECUR trialThe trial is evaluating the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in men with suspected biochemical recurrence of prostate cancer following treatment with curative intent.
Latest:
Emerging Therapies for Metastatic Castration-Resistant Prostate CancerRobert Dreicer, MD, describes the future of metastatic castration-resistant prostate cancer.
Latest:
Future Perspectives in the Treatment of Patients With Urinary StonesDrs Bechis and Semins discuss future developments in urinary stone management, emphasizing the potential for improved vacuum aspiration devices, combined intravenous and PCNL surgeries, and the hope for medications to dissolve stones.
Latest:
Demystifying Vector-Based Intravesical Gene Therapy for NMIBC: A New FrontierNeal Shore, MD, FACS, is a U.S. Chief Medical Officer at GenesisCare USA and Medical Director of the Carolina Urologic Research Center. He also was an investigator on the Phase 2 and 3 studies in the clinical trial program for nadofaragene firadenovec-vncg.
Latest:
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBCPanelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.
Latest:
The role of surgery continues to evolve in seminoma"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Diversity in Urology: Progress made, but there is more work to be doneKelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.
